EGFR and pancreatic neoplasm: Strikingly, the clinical response rate to ICI therapies remains unexpectedly poor inpatients with types of epithelial tumours that overexpress either wild-type (wt) or oncogenic alterations of the Epidermal Growth Factor Receptor (EGFR), such as lung, colon, prostate, or pancreas cancers [7,8,9,10].